Cupid Q2 FY25 income up 29.7%; PAT up 96.2%
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Q2 FY25 Total Income was at Rs. 85.4 crore
Hospital business revenues increase 13.9% to Rs. 1,655 crore
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
Subscribe To Our Newsletter & Stay Updated